文献速递乳腺癌放疗放疗物理与技术

乳腺癌术后立体定向部分乳腺照射的早期结局与大样本单中心剂量学经验

Large institutional experience of early outcomes and dosimetric findings with postoperative stereotactic partial breast irradiation in breast cancer.
PubMed 文献 · Radiother Oncol · 2023-12-22

分析2016年1月至2022年12月在本机构接受术后立体定向部分乳腺照射(S-PBI)的799例女性患者的剂量学与毒性结局,并与同机构468例超大分割全乳照射(UF-WBI)对照。S-PBI组急性毒性21.5%与UF-WBI组25.2%无显著差异(p=0.12),但所有危及器官剂量学参数均显著更低(均p<0.05)。作者认为S-PBI具有有利的剂量学和毒性特征,对于部分乳腺照射候选者,至少应考虑采用先进技术的外照射PBI而非传统基于全乳照射的方法。

要点

  • 799例患者共815侧乳房接受S-PBI,中位随访31.6个月,晚期毒性总发生率为4%。
  • S-PBI组急性毒性21.5% vs UF-WBI组25.2%(p=0.12),无显著差异。
  • S-PBI组所有危及器官剂量学参数均显著低于UF-WBI组(均p<0.05)。

核心结论

  • 在这一大样本队列中,S-PBI表现出有利的剂量学和毒性特征。
  • 作者认为,考虑到对周围组织辐射暴露的减少,对于部分乳腺照射候选者,至少应考虑采用先进技术的外照射部分乳腺照射而非传统基于全乳照射的方法。

研究设计与样本

  • 本研究分析了2016年1月至2022年12月期间在本机构接受术后立体定向部分乳腺照射(S-PBI)的799例女性患者。
  • 选择同机构接受超大分割全乳照射(UF-WBI)的468例作为对照组进行比较。
  • 主要终点为剂量学参数和放射相关毒性。

主要发现

  • 共799例患者的815侧乳房接受S-PBI,中位计划靶区(PTV)体积为89.6 cm3。
  • PTV平均剂量和最大剂量分别为处方剂量的96.2%和104.8%。
  • 接受50%处方剂量的同侧乳房体积为32.3±8.9%。
  • 同侧肺和心脏的平均剂量分别为2.5±0.9 Gy和0.65±0.39 Gy。
  • 急性毒性发生于175例患者(21.5%),主要为1级;中位随访31.6个月,晚期毒性总发生率为4%。

关键数值与推荐

  • 最常用的剂量分割方案为30 Gy分5次(91.7%),最常用技术为实时追踪的机器人立体定向放射系统(83.7%)。
  • 与UF-WBI组相比,S-PBI组急性毒性发生率相当(21.5% vs 25.2%,p=0.12),但所有危及器官的剂量学参数均显著更低(均p<0.05)。

临床怎么用

  • 作者认为,对于部分乳腺照射候选者,至少应考虑采用先进技术的外照射部分乳腺照射而非传统基于全乳照射的方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the dosimetric and toxicity outcomes of patients treated with postoperative stereotactic partial breast irradiation (S-PBI). METHODS: We identified 799 women who underwent S-PBI at our institution between January 2016 and December 2022. The most commonly used dose-fraction and technique were 30 Gy in 5 fractions (91.7 %) and a robotic stereotactic radiation system with real-time tracking (83.7 %). The primary endpoints were dosimetric parameters and radiation-related toxicities. For comparison, a control group undergoing ultra-hypofractionated whole breast irradiation (UF-WBI, n = 468) at the same institution was selected. RESULTS: A total of 815 breasts from 799 patients, with a median planning target volume (PTV) volume of 89.6 cm3, were treated with S-PBI. Treatment plans showed that the mean and maximum doses received by the PTV were 96.2 % and 104.8 % of the prescription dose, respectively. The volume of the ipsilateral breast that received 50 % of the prescription dose was 32.3 ± 8.9 %. The mean doses for the ipsilateral lung and heart were 2.5 ± 0.9 Gy and 0.65 ± 0.39 Gy, respectively. Acute toxicity occurred in 175 patients (21.5 %), predominantly of grade 1. Overall rate of late toxicity was 4 % with a median follow-up of 31.6 months. Compared to the UF-WBI group, the S-PBI group had comparably low acute toxicity (21.5 % vs. 25.2 %, p = 0.12) but significantly lower dosimetric parameters for all organs-at-risks (all p < 0.05). CONCLUSION: In this large cohort, S-PBI demonstrated favorable dosimetric and toxicity profiles. Considering the reduced radiation exposure to surrounding tissues, external beam PBI with advanced techniques should at least be considered over traditional WBI-based approaches for PBI candidates.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chang JS, Lee J, Vicini FA, et al. Large institutional experience of early outcomes and dosimetric findings with postoperative stereotactic partial breast irradiation in breast cancer. Radiother Oncol. 2023. PMID: 38142936. doi:10.1016/j.radonc.2023.110066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。